Avidity Biosciences (RNA) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Avidity Biosciences (NASDAQ: RNA):

• 6/11/2025 – Avidity Biosciences is now covered by analysts at Raymond James. They set a “strong-buy” rating and a $65.00 price target on the stock.
• 6/10/2025 – Avidity Biosciences had its price target raised by analysts at Barclays PLC from $57.00 to $59.00. They now have an “overweight” rating on the stock.
• 6/10/2025 – Avidity Biosciences had its price target raised by analysts at JPMorgan Chase & Co. from $57.00 to $59.00. They now have an “overweight” rating on the stock.
• 6/10/2025 – Avidity Biosciences had its price target raised by analysts at Citigroup Inc. from $70.00 to $75.00. They now have a “buy” rating on the stock.
• 6/9/2025 – Avidity Biosciences had its price target raised by analysts at Bank of America Co. from $48.00 to $54.00. They now have a “buy” rating on the stock.
• 6/9/2025 – Avidity Biosciences had its price target raised by analysts at Chardan Capital from $65.00 to $75.00. They now have a “buy” rating on the stock.
• 5/12/2025 – Avidity Biosciences had its price target lowered by analysts at HC Wainwright from $72.00 to $68.00. They now have a “buy” rating on the stock.
• 5/7/2025 – Avidity Biosciences had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.

Avidity Biosciences Trading Down 5.0%

Avidity Biosciences stock opened at $29.80 on Tuesday. Avidity Biosciences, Inc. has a 52 week low of $21.51 and a 52 week high of $56.00. The stock has a fifty day moving average price of $30.10 and a 200 day moving average price of $30.91. The firm has a market capitalization of $3.59 billion, a P/E ratio of -10.35 and a beta of 0.95.

Avidity Biosciences (NASDAQ:RNA) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $2.63 million. Avidity Biosciences had a negative net margin of 2,772.45% and a negative return on equity of 27.66%. As a group, equities analysts predict that Avidity Biosciences, Inc. will post -2.89 EPS for the current year.

Insider Activity at Avidity Biosciences

In other Avidity Biosciences news, insider Kathleen P. Gallagher sold 5,875 shares of Avidity Biosciences stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $27.83, for a total value of $163,501.25. Following the transaction, the insider now directly owns 50,554 shares of the company’s stock, valued at $1,406,917.82. The trade was a 10.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Sarah Boyce sold 31,540 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $31.06, for a total value of $979,632.40. Following the completion of the sale, the chief executive officer now owns 305,871 shares in the company, valued at $9,500,353.26. This trade represents a 9.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,678 shares of company stock worth $2,725,857 over the last ninety days. 3.83% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avidity Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Avidity Biosciences by 2.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,338,098 shares of the biotechnology company’s stock valued at $334,701,000 after purchasing an additional 295,275 shares during the period. Wellington Management Group LLP grew its stake in shares of Avidity Biosciences by 19.5% during the first quarter. Wellington Management Group LLP now owns 9,684,556 shares of the biotechnology company’s stock worth $285,888,000 after buying an additional 1,578,459 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Avidity Biosciences by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 9,431,911 shares of the biotechnology company’s stock valued at $274,280,000 after purchasing an additional 205,027 shares in the last quarter. Avoro Capital Advisors LLC increased its position in Avidity Biosciences by 9.1% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,500,000 shares of the biotechnology company’s stock valued at $218,100,000 after acquiring an additional 625,000 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Avidity Biosciences by 44.1% in the 4th quarter. Janus Henderson Group PLC now owns 7,053,010 shares of the biotechnology company’s stock valued at $205,134,000 after buying an additional 2,156,844 shares during the last quarter.

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.